Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIC/FTC/TAF in HIV with first-generation INSTI resistance
ChiCTR2600128553Phase 4Not yet recruiting
- Sponsor
- Beijing Ditan Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bictegravir, emtricitabine and tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 cohorts), sponsored by Beijing Ditan Hospital. Primary endpoint: HIV RNA load. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
bictegraviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2600128553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128553.